Enhancing preparedness and protecting the American people from anthrax, smallpox,
botulinum toxin, and filoviruses by supporting the advanced development of medical
countermeasures through regulatory approval and procurement.
The Antivirals and Antitoxins program partners with industry to develop safe and effective therapeutics for disease caused by anthrax, botulinum toxin, smallpox, and filoviruses. These high consequence pathogens would cause significant mortality if released into the US population, and the products we develop are designed to mitigate the consequences of deliberate or naturally occurring outbreaks of these biological threats.
Since the establishment of BARDA in 2006, a portfolio of FDA-approved therapeutics for these four threats has been developed and procured for national security preparedness. We continue to build on these successes by developing products that are sustainable, improve operational logistics, and diversify the current countermeasures portfolio.
BARDA and partners are seeking solutions to the problems of severe and persistent filovirus infection.
ABOUT THE EVENT
ALL STAKEHOLDERS INVITED - REGISTRATIONCompanies and others interested in the topic area are encouraged to attend March 9, 2022. The event is open to the public, but space is limited. Thank you for your interest; however, registration for the event is now closed.